Verified China Drug Approvals
Launch release displays only manually verified NMPA approval records (19 records across 15 drugs) tied to our 2026 catalog sample. Approval dates and public announcement/delivery dates are stored separately.
| Approval Date | Drug & Approval No. | Event Type & Approved Scope | Authority & MAH | Source |
|---|---|---|---|---|
Oct 15, 2026 2026-10-15 Notice: 2026-10-15 | Insulin icodec / Semaglutide 依柯胰岛素司美格鲁肽注射液 国药准字SJ20260018 Pre-filled pen (SJ20260018 / SJ20260019 / SJ20260020) | Supplemental Indication Expanded to adults with Type 2 Diabetes inadequately controlled on oral antidiabetic drugs (OADs); initial March 2026 approval covered patients uncontrolled on basal insulin or GLP-1 RAs. 新增适用于接受口服降糖药(OADs)治疗血糖控制不佳的成人2型糖尿病患者(首发适应症于2026年3月获批用于基础胰岛素或GLP-1RA控制不佳患者)。 | NMPA (China) Novo Nordisk A/S 诺和诺德 | Verified 2026-11-21 |
Sep 29, 2026 2026-09-29 Notice: 2026-09-29 | Datopotamab deruxtecan 注射用德达博妥单抗 国药准字SJ20250021 100mg/瓶 | Supplemental Indication Supplemental indication for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitor therapy (note: 2026 NRDL covers HR+/HER2- BC only). 适用于不适合接受PD-1/PD-L1抑制剂治疗的不可切除或转移性三阴性乳腺癌(TNBC)成人患者。 | NMPA (China) Daiichi Sankyo / AstraZeneca 第一三共 / 阿斯利康 | Verified 2026-11-21 |
Dec 22, 2025 2025-12-22 Notice: 2025-12-22 | Eplontersen sodium 依普隆特生钠注射液 国药准字HJ20250151 | Initial Approval Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adult patients. 适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。 | NMPA (China) AstraZeneca AB 阿斯利康 | Verified 2026-11-21 |
Sep 16, 2025 2025-09-16 | Mazdutide 玛仕度肽注射液 国药准字H20250036 0.5ml:2mg / 4mg / 6mg | Supplemental Indication Glycemic control in adults with Type 2 Diabetes mellitus (monotherapy or in combination with oral antidiabetic agents); covers H20250036 / H20250037 / H20250038. 本品适用于成人2型糖尿病患者的血糖控制(单药治疗或联合二甲双胍等口服降糖药)。 | NMPA (China) Innovent Biologics (Suzhou) Co., Ltd. 信达生物制药(苏州)有限公司 | Verified 2026-11-20 |
Aug 22, 2025 2025-08-22 Notice: 2025-08-22 | Datopotamab deruxtecan 注射用德达博妥单抗 国药准字SJ20250021 100mg/瓶 | Initial Approval Adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced setting. 适用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、HER2阴性乳腺癌成人患者。 | NMPA (China) Daiichi Sankyo / AstraZeneca 第一三共 / 阿斯利康 | Verified 2026-11-21 |
Jun 24, 2025 2025-06-24 Notice: 2025-06-30 | Mazdutide 玛仕度肽注射液 国药准字H20250036 0.5ml:2mg | Initial Approval Chronic weight management in adults as an adjunct to diet and physical activity (initial BMI ≥ 28 kg/m² obesity, or BMI ≥ 24 kg/m² overweight with at least one weight-related comorbidity). 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。 | NMPA (China) Innovent Biologics (Suzhou) Co., Ltd. 信达生物制药(苏州)有限公司 | Verified 2026-11-20 |
Jun 24, 2025 2025-06-24 Notice: 2025-06-30 | Mazdutide 玛仕度肽注射液 国药准字H20250037 0.5ml:4mg | Initial Approval Chronic weight management in adults (4 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30). 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。 | NMPA (China) Innovent Biologics (Suzhou) Co., Ltd. 信达生物制药(苏州)有限公司 | Verified 2026-11-20 |
Jun 24, 2025 2025-06-24 Notice: 2025-06-30 | Mazdutide 玛仕度肽注射液 国药准字H20250038 0.5ml:6mg | Initial Approval Chronic weight management in adults (6 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30). 本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。 | NMPA (China) Innovent Biologics (Suzhou) Co., Ltd. 信达生物制药(苏州)有限公司 | Verified 2026-11-20 |
Mar 18, 2025 2025-03-18 Notice: 2025-03-21 | Tazemetostat hydrobromide 氢溴酸他泽司他片 国药准字HJ20250031 200mg | Initial Approval Monotherapy for adult patients with EZH2-mutation-positive relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. 单药用于既往接受过至少两种系统性治疗后的EZH2突变阳性复发或难治性滤泡性淋巴瘤(FL)成人患者。 | NMPA (China) Epizyme, Inc. Epizyme / 和黄医药 | Verified 2026-11-21 |
Dec 25, 2024 2024-12-25 Notice: 2024-12-31 | Zolbetuximab 注射用佐妥昔单抗 国药准字SJ20240050 100mg/瓶 | Initial Approval First-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy. 联合含氟尿嘧啶类和铂类药物化疗,用于CLDN18.2阳性、人表皮生长因子受体2(HER2)阴性的局部晚期不可切除或转移性胃或胃食管交界处(GEJ)腺癌患者的一线治疗。 | NMPA (China) Astellas Pharma 安斯泰来制药 | Verified 2026-11-20 |
Nov 27, 2024 2024-11-27 Notice: 2024-11-27 | Sacituzumab tirumotecan 注射用芦康沙妥珠单抗 国药准字S20240052 200mg/瓶 | Initial Approval Adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one in the advanced or metastatic setting). 用于既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌成人患者。 | NMPA (China) Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 四川科伦博泰生物医药股份有限公司 | Verified 2026-11-20 |
Sep 26, 2024 2024-09-26 Notice: 2024-10-08 | Tofersen 托夫生注射液 国药准字HJ20240102 15ml:0.1g (100mg) | Initial Approval Conditional approval for adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene. 用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者(附条件批准)。 | NMPA (China) Biogen MA Inc. Biogen MA Inc. | Verified 2026-11-21 |
Nov 7, 2023 2023-11-07 Notice: 2023-11-08 | Inaticabtagene autoleucel 纳基奥仑赛注射液 国药准字S20230065 | Initial Approval Conditional approval for adult relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL); later expanded to adult r/r large B-cell lymphoma (r/r LBCL). 附条件批准用于治疗成人复发或难治性B细胞急性淋巴细胞白血病(r/r B-ALL);后续扩展至成人复发或难治性大B细胞淋巴瘤(r/r LBCL)。 | NMPA (China) Juventas Cell Therapy Ltd. 合源生物科技股份有限公司 | Verified 2026-11-21 |
Jun 29, 2023 2023-06-29 Notice: 2023-06-29 | Sapropterin dihydrochloride 盐酸沙丙蝶呤片 国药准字H20233796 100mg | Initial Approval Treatment of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency in responsive patients (first domestic generic approval). 适用于对本品治疗有反应的四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA)。 | NMPA (China) Shandong New Time Pharmaceutical Co., Ltd. 山东新时代药业有限公司 | Verified 2026-11-21 |
Feb 21, 2023 2023-02-21 Notice: 2023-02-24 | Trastuzumab deruxtecan 注射用德曲妥珠单抗 国药准字SJ20230005 100mg/瓶 | Initial Approval Initial approval for unresectable/metastatic HER2-positive adult breast cancer after ≥1 prior anti-HER2 regimen; subsequently expanded across HER2-low/ultralow BC, gastric/GEJ cancer, and HER2-mutant NSCLC. 首发获批用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者;后续扩展至HER2低/超低表达乳腺癌、胃癌及HER2突变NSCLC。 | NMPA (China) Daiichi Sankyo Europe GmbH 第一三共欧洲公司 | Verified 2026-11-21 |
Jan 30, 2022 2022-01-30 Notice: 2022-02-09 | Ivosidenib 艾伏尼布片 国药准字HJ20220002 250mg | Initial Approval Initial approval for adult relapsed or refractory AML with a susceptible IDH1 mutation; later expanded to first-line IDH1-mutated AML in combination with azacitidine. 首发获批用于携带易感IDH1突变的复发或难治性急性髓系白血病(AML)成人患者;后续扩展至联合阿扎胞苷一线治疗新诊断IDH1突变AML。 | NMPA (China) Servier Pharmaceuticals LLC 施维雅药厂有限责任公司 | Verified 2026-11-21 |
Sep 1, 2021 2021-09-01 Notice: 2021-09-03 | Relmacabtagene autoleucel 瑞基奥仑赛注射液 国药准字S20210035 | Initial Approval Adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy; subsequently expanded to r/r FL and r/r MCL. 经过二线或以上系统性治疗后成人患者的复发或难治性大B细胞淋巴瘤(r/r LBCL);后续获批滤泡性淋巴瘤(FL)及套细胞淋巴瘤(MCL)适应症。 | NMPA (China) JW Therapeutics (Shanghai) Co., Ltd. 上海药明巨诺生物科技有限公司 | Verified 2026-11-20 |
May 7, 2021 2021-05-07 Notice: 2021-05-07 | Pamiparib 帕米帕利胶囊 国药准字H20210016 20mg | Initial Approval Conditional approval for patients with gBRCA-mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer after two or more prior lines of chemotherapy. 附条件批准用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者。 | NMPA (China) BeiGene (Suzhou) Co., Ltd. 百济神州(苏州)生物科技有限公司 | Verified 2026-11-21 |
Jun 17, 2020 2020-06-17 Notice: 2020-06-19 | Dupilumab 度普利尤单抗注射液 国药准字SJ20200017 300mg (2ml) | Initial Approval Initial approval for adult moderate-to-severe atopic dermatitis; subsequently expanded across prurigo nodularis, asthma, eosinophilic COPD, and bullous pemphigoid. 首发获批用于外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎;后续陆续获批结节性痒疹、哮喘、COPD、大疱性类天疱疮等多项适应症。 | NMPA (China) Sanofi Winthrop Industrie 赛诺菲温特鲁普工业公司 | Verified 2026-11-21 |